期刊文献+

RCC5基因在肾透明细胞癌中的表达及临床意义

The expression and clinical significance of RCC5 in clear cell renal cell carcinoma
下载PDF
导出
摘要 目的明确RCC5在肾透明细胞癌(ccRCC)组织中的表达水平及其对肾癌患者预后的影响。方法通过荧光定量PCR方法对54对ccRCC患者标本(包括癌组织和癌旁正常组织)的RCC5mRNA进行分析;并运用免疫组化对82对配对的癌组织和癌旁正常组织切片及161例癌组织切片进行染色;运用统计学方法分析RCC5的表达量和患者的临床特点之间关系。结果荧光定量PCR结果显示92.59%(50/54))的肾癌组织中RCC5表达水平明显高于癌旁正常组织(P<0.001);82对癌组织及癌旁正常组织切片免疫组化显示,92.68%(76/82)的癌组织RCC5表达水平高于癌旁正常组织(P<0.001);同时发现RCC5的表达水平与性别、肿瘤直径、病理分期、分级、TNM分期和复发率相关;RCC5高表达的患者预后一般较低表达者差,多元分析显示RCC5表达上调是ccRCC的独立预后因素。结论 RCC5的表达水平和ccRCC预后之间存在明显相关性;研究发现RCC5表达上调的患者预后较差,RCC5可能是一个新颖并且有临床价值的预后标志物。 Objective To identify the expression of RCC5 in clear cell renal cell carcinoma(ccRCC) and its clinical significance on the prognosis of ccRCC.Methods The expressions of RCC5mRNA in 54 cases of ccRCC and adjacent normal tissues were examined with real time RT-PCR.The expressions of RCC5 protein in 161 specimens of ccRCC and 82 paired adjacent normal renal tissues were detected with immunohistochemical method.The relationship between the expression of RCC5 and clinical features and prognosis of ccRCC was statistcally analyzed.Results The mRNA level of RCC5 was significantly higher in 50/54(92.6%) ccRCC tissues compared with that in the adjacent normal tissues(P0.001).The RCC5 protein expression was higher in 76/82(92.6%) ccRCC tissues compared with that in the adjacent normal tissues(P0.001).Moreover,there was a significant correlation between RCC5 expression and gender,tumor size,pathologic stage,TNM classification and recurrence.Patients with higher RCC5 expression had shorter overall survival time than those with lower RCC5 expression.Multivariate analysis indicated that RCC5 protein upregulation was an independent predictor for poor survival of patients with ccRCC.Conclusions Upregulation of RCC5 expression indicates poor prognosis of ccRCC,which can serve as a novel prognostic marker of ccRCC.
出处 《现代泌尿外科杂志》 CAS 2012年第3期245-248,共4页 Journal of Modern Urology
基金 广东省医学科研基金课题(No.A2011562)
关键词 RCC5基因 RCC5mRNA 荧光定量PCR 肾透明细胞癌 RCC5 RCC5mRNA real time PCR clear cell renal cell carcinoma
  • 相关文献

参考文献10

  • 1MCLAUGHLIN JK,LIPWORTH L,TARONE RE.Epidemiologic aspects of renal cell carcinoma[J].Semin Oncol,2006,33:527.
  • 2MOTZER RJ,BANDER NH,NANUS DM:Renal-cell carcinoma[J].N Engl J Med,1996,335(12):865.
  • 3JANZEN NK,KIM HL,FIGLIN RA,et al.Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease[J].Urol Clin North Am,2003,30:843.
  • 4CHOW WH,DONG LM,DEVESA SS.Epidemiology and risk factors for kidney cancer[J].Nat Rev Urol,2010,7(5):245.
  • 5MCCREDIE M.Bladder and kidney cancers[J].Cancer Surv,1994,19:343.
  • 6LJUNGBERG B,COWAN NC,HANBURY DC,et al.EAU guidelines on renal cell carcinoma:the 2010 update[J].Eur Urol,2010,58(3):398.
  • 7SABATINO M,KIM-SCHULZE S,PANELLI MC,et al.Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy[J].J Clin Oncol,2009,27:2645.
  • 8BANKS RE,CRAVEN RA,HARNDEN P,et al.Key clinical issues in renal cancer:a challenge for proteomics[J].World J Urol,2007,25:537.
  • 9SABATINO M,KIM-SCHULZE S,PANELLI MC,et al.Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy[J]. J Clin Oncol,2009,27:2645.
  • 10BANKS RE,CRAVEN RA,HARNDEN P,et al.Key clinical issues in renal cancer:a challenge for proteomics[J].World J Urol,2007,25: 537.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部